TSX:NUMI • CA67054W1032
The current stock price of NUMI.CA is 0.05 CAD. Today NUMI.CA is up by 42.86%. In the past month the price increased by 25%. In the past year, price decreased by -58.33%.
ChartMill assigns a technical rating of 4 / 10 to NUMI.CA. When comparing the yearly performance of all stocks, NUMI.CA turns out to be only a medium performer in the overall market: it outperformed 45.79% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to NUMI.CA. NUMI.CA may be in some trouble as it scores bad on both profitability and health.
On January 13, 2025 NUMI.CA reported an EPS of -0.02 and a revenue of 4.35M. The company missed EPS expectations (-96.08% surprise) and missed revenue expectations (-21.98% surprise).
For the next year, analysts expect an EPS growth of 58.33% and a revenue growth -18.04% for NUMI.CA
Over the last trailing twelve months NUMI.CA reported a non-GAAP Earnings per Share(EPS) of -0.11. The EPS increased by 37.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -213.24% | ||
| ROE | -644.74% | ||
| Debt/Equity | 0.95 |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| BHC | BAUSCH HEALTH COS INC | 1.33 | 2.9B | ||
| CRON | CRONOS GROUP INC | 36.43 | 1.353B | ||
| TLRY | TILRAY BRANDS INC | N/A | 1.174B | ||
| DHT-UN | DRI HEALTHCARE TRUST | 7.13 | 900.394M | ||
| DHT-U | DRI HEALTHCARE TRUST | 5.09 | 643.685M | ||
| GUD | KNIGHT THERAPEUTICS INC | 129.86 | 615.088M | ||
| WEED | CANOPY GROWTH CORP | N/A | 589.898M | ||
| NGEN | NERVGEN PHARMA CORP | N/A | 434.91M | ||
| CPH | CIPHER PHARMACEUTICALS INC | 27.62 | 376.419M | ||
| TSND | TERRASCEND CORP | N/A | 323.031M | ||
| HITI | HIGH TIDE INC | 25.5 | 298.996M | ||
| ACB | AURORA CANNABIS INC | 13.92 | 271.074M | ||
| OGI | ORGANIGRAM GLOBAL INC | 21.61 | 251.197M |
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Toronto Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find more growth stocks the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
Numinus Wellness, Inc. engages in the development of psychedelic-centered therapeutic products. The company is headquartered in Montreal, Quebec. The firm focuses on advancing traditional and behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies. Its segments include Clinical research operations, Practitioner Training, Clinic network, and Corporate. Clinical research operations segment is focused on licensed psychedelic research and provides clinical research management services to academic institutions and biotechnology companies. Practitioner Training segment is engaged in education and training for research and drug development organizations to support clinical trials and commercialization efforts. Clinic network segment includes wellness clinics, which is engaged in providing clinical services from psychedelic-assisted therapies, transcranial magnetic stimulation, and psychiatric and medical model management. Corporate segment includes finance, marketing, information technology, legal, and human resources.
NUMINUS WELLNESS INC
393 Laurier Ave W
MONTREAL QUEBEC V6B 1R4 CA
CEO: Payton Nyquvest
Employees: 0
Phone: 18336864687.0
Numinus Wellness, Inc. engages in the development of psychedelic-centered therapeutic products. The company is headquartered in Montreal, Quebec. The firm focuses on advancing traditional and behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies. Its segments include Clinical research operations, Practitioner Training, Clinic network, and Corporate. Clinical research operations segment is focused on licensed psychedelic research and provides clinical research management services to academic institutions and biotechnology companies. Practitioner Training segment is engaged in education and training for research and drug development organizations to support clinical trials and commercialization efforts. Clinic network segment includes wellness clinics, which is engaged in providing clinical services from psychedelic-assisted therapies, transcranial magnetic stimulation, and psychiatric and medical model management. Corporate segment includes finance, marketing, information technology, legal, and human resources.
The current stock price of NUMI.CA is 0.05 CAD. The price increased by 42.86% in the last trading session.
NUMI.CA does not pay a dividend.
NUMI.CA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
NUMINUS WELLNESS INC (NUMI.CA) operates in the Health Care sector and the Pharmaceuticals industry.
The Revenue of NUMINUS WELLNESS INC (NUMI.CA) is expected to decline by -18.04% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
NUMINUS WELLNESS INC (NUMI.CA) has a market capitalization of 16.12M CAD. This makes NUMI.CA a Nano Cap stock.